Author + information
To compare the effectiveness and safety of the different methods of anticoagulation with rivaroxaban in patient after radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF).
178 patients with non-valvularparoxysmal atrial fibrillation treated by radiofrequency ablation in General Hospital, Shenyang Military Area Command, from January 2015 to October 2016 were selected as the research objects. The 178 patients were divided into A Group (102 patients) and B Group (76 patients). In A Group, rivaroxaban 10mg, bid, In B Group, rivaroxaban 20mg, QD was given for 3 month. All the patients took the same anticoagulant during the whole period of anticoagulation therapy.
There were no differences in baseline characteristics between two groups in Age, Sex, Hypertension, Diabetes mellitus, Paroxysmal atrial fibrillation and other clinical data. Operation Timex-ray exposure, surgical complications and other complications no differences in baseline characteristics between two groups. The patients were followed up for 3 months. Comparison of the efficacy and safety between 2 groups. There were no major bleeding events in both groups. There were no significant differences in minor bleeding events between A Group (2/102 cases)1 cases of gingival bleeding, another 1 cases of blood in the sputum, all did not reduce the drug, symptom remission, and B Group (1/76cases,this is blood in the sputum).
The application two different ways of administration of rivamxaban as anticoagulant therapy for patients with atrial fibrillation after radiofrequency catheter ablation are safe and effective, rivaroxaban 20mg, QD may be obedience is better, patients are easy to accept.